Edgemont Pharmaceuticals, LLC

Quick facts

Phase 3 pipeline

• Extended-release lorazepam · Psychiatry / Neurology
  Extended-release lorazepam is a benzodiazepine that enhances the inhibitory neurotransmitter GABA at the GABA-A receptor, producing anxiolytic, sedative, and anticonvulsant effects.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Edgemont Pharmaceuticals, LLC portfolio CI brief
• Edgemont Pharmaceuticals, LLC pipeline updates RSS